• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

    5/14/25 8:00:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADCT alert in real time by email

    LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML); ZYNLONTA® plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability

    Forty patient enrollment reached in LOTIS-7 trial dose expansion arm in patients with relapsed/refractory DLBCL

    Cash runway expected to fund multiple catalysts into the second half of 2026

    Company to host conference call today at 8:30 a.m. EDT

    LAUSANNE, Switzerland, May 14, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2025, and provided recent operational updates.

    ADC Therapeutics logo (PRNewsfoto/ADC Therapeutics SA)

    "We are encouraged by the promising LOTIS-7 abstract data, which we believe demonstrate the potential for ZYNLONTA® plus glofitamab to be a best-in-class combination in a dynamic market," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "Coupled with the progress of our LOTIS-5 confirmatory trial, we are confident in our path forward and the potential of ZYNLONTA as we pursue the substantially larger opportunity in earlier lines of DLBCL therapy."

    First Quarter 2025 Operational Updates & Recent Highlights

    • Abstract accepted for LOTIS-7 data presentations at EHA2025 and ICML. As of the abstract cutoff date of January 17, 2025, 31 patients received ≥1 ZYNLONTA dose and were safety evaluable, with 22 patients evaluable for efficacy. ZYNLONTA plus glofitamab (COLUMVI®) demonstrated an overall response rate (ORR) of 95.5% and complete response (CR) rate of 90.9%. Four of the efficacy evaluable patients (2 each at 120µg/kg and 150 µg/kg) converted to CR within 3 weeks after the data cutoff and are included as CRs. Twenty of 21 responders have remained in response and the median duration of response has not been reached. Manageable safety and tolerability were observed across all 31 safety evaluable patients. Updated data will be presented during a poster session on Saturday, June 14 at 12:30 p.m. ET at EHA2025 taking place in Milan, Italy from June 12–15, 2025 and an oral presentation at ICML taking place in Lugano, Switzerland from June 17-21, 2025.
    • Enrollment of 40 patients reached in LOTIS-7 dose expansion arm. Forty patients have been enrolled in the dose expansion arm of the Phase 1b clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab in patients with r/r DLBCL. The Company expects to provide an update on the LOTIS-7 trial in the second half of 2025.
    • Abstract accepted for LOTIS-5 trial safety run-in data presentation at EHA2025. As of the abstract cutoff date of October 4, 2024, the safety run-in data included 20 patients, from LOTIS-5, a Phase 3, randomized trial of ZYNLONTA plus rituximab in patients with r/r DLBCL. Fixed treatment duration of this combination showed no new safety signals and demonstrated encouraging antitumor activity, with signs of durable responses in r/r DLBCL/HGBL patients >28 months after end of treatment. The data will be presented during a poster session on Saturday, June 14 at 12:30 p.m. ET at EHA2025.
    • LOTIS-5 remains on track to reach prespecified progression-free survival (PFS) events by end of 2025. After the prespecified number of PFS events is reached and data are available, the Company expects to provide topline data on the Phase 3 confirmatory trial evaluating ZYNLONTA in combination with rituximab in patients with 2L+ DLBCL.
    • Abstract accepted for presentation of marginal zone lymphoma (MZL) data at ICML. A poster entitled, "Updated analysis of a phase 2 multicenter study of the loncastuximab in relapsed/refractory marginal zone lymphoma demonstrates high rate of complete responses" will be presented at ICML. This single-arm, open-label investigator-initiated study is being conducted at the Sylvester Comprehensive Cancer Center at University of Miami and City of Hope, and led by Izidore Lossos, MD, Professor, Director, Lymphoma Program at the Sylvester Comprehensive Cancer Center, University of Miami.
    • Discontinuation of ADCT-602 trial. Based on the available clinical data, the Phase 1/2 ADCT-602 clinical trial, sponsored by The University of Texas MD Anderson Cancer Center, evaluating ADCT-602 in patients with r/r B-cell acute lymphoblastic leukemia will be discontinued.
    • Preclinical programs highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2025. Data from preclinical studies of our exatecan-based ADCs targeting Claudin-6 (CLDN6), prostate-specific membrane antigen (PSMA), and Alanine, Serine, Cysteine Transporter 2 (ASCT2) were featured.

    First Quarter 2025 Financial Results

    • Product Revenues: ZYNLONTA generated net product revenues of $17.4 million for the first quarter of 2025 as compared to $17.8 million for the first quarter of 2024.
    • License Revenues and Royalties: License revenue and royalties were $5.6 million for the first quarter of 2025 as compared to $0.2 million for the first quarter of 2024. In March 2025, the Company recognized $5.0 million in license revenue in connection with a milestone payment due upon ZYNLONTA's approval by Health Canada for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy.
    • Research and Development (R&D) Expense: R&D expense was $28.9 million for the first quarter of 2025 as compared to $25.7 million for the first quarter of 2024. The increase is primarily attributable to a net increase in spending on our next-generation investigational ADCs.
    • Selling and Marketing (S&M) Expense: S&M expense was $10.6 million for the first quarter of 2025 as compared to $11.4 million for the first quarter of 2024. The quarter-over-quarter decrease in S&M expense was primarily due to lower marketing and advertising and travel-related costs, partially offset by higher share-based compensation expense.
    • General & Administrative (G&A) Expense: G&A expense was $10.0 million for the first quarter of 2025 as compared to $12.0 million for the first quarter of 2024. The quarter-over-quarter decrease in G&A expense was primarily related to lower professional fees and VAT recoveries.
    • Net Loss: Net loss for the quarter ended March 31, 2025 was $38.6 million, or a net loss of $0.36 per basic and diluted share, as compared to net loss of $46.6 million, or a net loss of $0.56 per basic and diluted share for the same period in 2024. The decrease in net loss during the quarter is primarily attributable to higher license revenues and royalties and lower other expense.
    • Adjusted Net Loss: Adjusted net loss, which is a non-GAAP financial measure, was $24.0 million, or an adjusted net loss of $0.22 per basic and diluted share for the quarter ended March 31, 2025 as compared to adjusted net loss of $31.1 million, or $0.38 per basic and diluted share, for the same period in 2024. The decrease in adjusted net loss during the quarter is primarily attributable to higher license revenues and royalties and lower operating expenses, as adjusted for share-based compensation.
    • Cash and cash equivalents: As of March 31, 2025, cash and cash equivalents were $194.7 million, compared to $250.9 million as of December 31, 2024, a change primarily driven by the timing of payments of the annual discarded drug rebate, annual bonuses and lower cash collections and partner reimbursements. The Company currently expects its cash runway to extend into the second half of 2026.

    Conference Call Details

    ADC Therapeutics management will host a conference call and live audio webcast to discuss first quarter 2025 financial results and provide a company update today at 8:30 a.m. Eastern Time. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. A live webcast of the call will be available under "Events & Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

    About ZYNLONTA®

    ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.

    The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Please see full prescribing information including important safety information about ZYNLONTA at www.ZYNLONTA.com.

    ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.

    About ADC Therapeutics

    ADC Therapeutics (NYSE:ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

    ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

    ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn.

    ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

    Use of Non-GAAP Financial Measures

    In addition to financial information prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP), this document also contains certain non-GAAP financial measures based on management's view of performance including:

    • Adjusted total operating expenses
    • Adjusted net loss
    • Adjusted net loss per share

    Management uses such measures internally when monitoring and evaluating our operational performance, generating future operating plans and making strategic decisions regarding the allocation of capital. We believe that these adjusted financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and facilitate operating performance comparability across both past and future reporting periods. These non-GAAP measures have limitations as financial measures and should be considered in addition to, and not in isolation or as a substitute for, the information prepared in accordance with GAAP. When preparing these supplemental non-GAAP measures, management typically excludes certain GAAP items that management does not believe are indicative of our ongoing operating performance. Furthermore, management does not consider these GAAP items to be normal, recurring cash operating expenses; however, these items may not meet the GAAP definition of unusual or non-recurring items. Since non-GAAP financial measures do not have standardized definitions and meanings, they may differ from the non-GAAP financial measures used by other companies, which reduces their usefulness as comparative financial measures. Because of these limitations, you should consider these adjusted financial measures alongside other GAAP financial measures.

    The following items are excluded from adjusted total operating expenses:

    Shared-Based Compensation Expense: We exclude share-based compensation expense from our adjusted financial measures because share-based compensation expense, which is non-cash, fluctuates from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. Share-based compensation expense has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.

    The following items are excluded from adjusted net loss and adjusted net loss per share:

    Shared-Based Compensation Expense: We exclude share-based compensation expense from our adjusted financial measures because share-based compensation expense, which is non-cash, fluctuates from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. Share-based compensation expense has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.

    Certain Other Items: We exclude certain other significant items that we believe do not represent the performance of our business, from our adjusted financial measures. Such items are evaluated by management on an individual basis based on both quantitative and qualitative aspects of their nature. While not all-inclusive, examples of certain other significant items excluded from our adjusted financial measures would be: changes in the fair value of warrant obligations and the effective interest expense associated with the senior secured term loan facility and the effective interest expense and cumulative catch-up adjustments associated with the deferred royalty obligation under the royalty purchase agreement with HealthCare Royalty Partners.

    See the attached Reconciliation of GAAP Measures to Non-GAAP Measures for explanations of the amounts excluded and included to arrive at the non-GAAP financial measures.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML, the timing of the PFS events for LOTIS-5 and the results of the trial, the expected cash runway into the second half of 2026 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; the Company's ability to grow ZYNLONTA® revenue in the United States; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying  FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

    ADC Therapeutics SA

    Condensed Consolidated Statements of Operations (Unaudited)

    (in thousands, except for share and per share data)

     





    For the Three Months Ended March 31,





    2025



    2024

    Revenue









      Product revenues, net



    $         17,404



    $         17,848

      License revenues and royalties



    5,629



    205

    Total revenue, net



    23,033



    18,053

    Operating expense









    Cost of product sales



    (2,061)



    (2,510)

    Research and development



    (28,928)



    (25,735)

    Selling and marketing



    (10,553)



    (11,390)

    General and administrative



    (9,955)



    (12,031)

    Total operating expense



    (51,497)



    (51,666)

    Loss from operations



    (28,464)



    (33,613)











    Other income (expense)









    Interest income



    2,054



    2,948

    Interest expense



    (12,230)



    (12,496)

    Other, net



    203



    (2,595)

    Total other expense, net



    (9,973)



    (12,143)

    Loss before income taxes



    (38,437)



    (45,756)

    Income tax expense



    (165)



    (163)

    Loss before equity in net losses of joint venture



    (38,602)



    (45,919)

    Equity in net losses of joint venture



    —



    (687)

    Net loss



    $       (38,602)



    $       (46,606)











    Net loss per share









    Net loss per share, basic and diluted



    $            (0.36)



    $           (0.56)

    Weighted average shares outstanding, basic and diluted



    107,202,374



    82,552,322

     

    ADC Therapeutics SA

    Condensed Consolidated Balance Sheets (Unaudited)

    (in thousands)

     





    March 31, 2025



    December 31, 2024

    ASSETS









    Current assets









    Cash and cash equivalents



    $            194,701



    $            250,867

    Accounts receivable, net



    31,762



    20,316

    Inventory



    17,447



    18,387

    Prepaid expenses



    6,899



    8,370

    Other current assets



    7,180



    9,450

    Total current assets



    257,989



    307,390

    Non-current assets









    Property and equipment, net



    5,156



    5,075

    Operating lease right-of-use assets



    8,231



    8,354

    Other long-term assets



    1,163



    1,161

    Total assets



    $            272,539



    $            321,980











    LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY









    Current liabilities









    Accounts payable



    $              15,592



    $              18,029

    Accrued expenses and other current liabilities



    42,202



    62,440

    Total current liabilities



    57,794



    80,469











    Deferred royalty obligation, long-term



    326,792



    320,093

    Senior secured term loans



    113,823



    113,632

    Operating lease liabilities, long-term



    7,907



    7,995

    Other long-term liabilities



    4,446



    2,433

    Total liabilities



    510,762



    524,622











    Total shareholders' (deficit) equity



    (238,223)



    (202,642)











    Total liabilities and shareholders' (deficit) equity



    $            272,539



    $            321,980

     

    ADC Therapeutics SA

    Reconciliation of GAAP Measures to Non-GAAP Measures (Unaudited)

    (in thousands, except for share and per share data)

     





    Three Months Ended March 31,

    (in thousands)



    2025



    2024



    Change



    % Change

    Total operating expense



    $     (51,497)



    $    (51,666)



    $        169



    — %

    Adjustments:

















    Share-based compensation expense (i)



    2,421



    158



    2,263



    1432 %

    Adjusted total operating expenses



    $     (49,076)



    $    (51,508)



    $     2,432



    (5) %

     





    Three Months Ended March 31,

    in thousands (except for share and per share data)



    2025



    2024

    Net loss



    $     (38,602)



    $       (46,606)

    Adjustments:









    Share-based compensation expense (i)



    2,421



    158

    Deerfield warrants obligation, change in fair value expense (ii)



    —



    3,068

    Effective interest expense on senior secured term loan facility (iii)



    3,785



    4,403

    Deferred royalty obligation interest expense (iv)



    8,445



    8,093

    Deferred royalty obligation cumulative catch-up adjustment income (iv)



    (12)



    (263)

    Adjusted net loss



    $     (23,963)



    $       (31,147)











    Net loss per share, basic and diluted



    $         (0.36)



    $           (0.56)

    Adjustment to net loss per share, basic and diluted



    0.14



    0.18

    Adjusted net loss per share, basic and diluted



    $         (0.22)



    $           (0.38)

    Weighted average shares outstanding, basic and diluted



    107,202,374



    82,552,322

    (i) 

    Share-based compensation expense represents the cost of equity awards issued to our directors, management and employees. The fair value of awards is computed at the time the award is granted and is recognized over the requisite service period less actual forfeitures by a charge to the statement of operations and a corresponding increase in additional paid-in capital within equity. These accounting entries have no cash impact.

     

    (ii)

    Change in the fair value of the Deerfield warrant obligation results from the valuation at the end of each accounting period. There are several inputs to these valuations, but those most likely to result in significant changes to the valuations are changes in the value of the underlying instrument (i.e., changes in the price of our common shares) and changes in expected volatility in that price. These accounting entries have no cash impact.

     

    (iii) 

    Effective interest expense on senior secured term loans relates to the increase in the value of our loans in accordance with the amortized cost method.

     

    (iv)

    Deferred royalty obligation interest expense relates to the accretion expense on our deferred royalty obligation pursuant to the royalty purchase agreement with HCR and cumulative catch-up adjustments related to changes in the expected payments to HCR based on a periodic assessment of our underlying revenue projections.

    CONTACTS:

    Investors

    Media

    Marcy Graham

    Nicole Riley

    ADC Therapeutics

    ADC Therapeutics

    [email protected] 

    [email protected] 

    +1 650-667-6450

    +1 862-926-9040

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-reports-first-quarter-2025-financial-results-and-provides-operational-update-302454627.html

    SOURCE ADC Therapeutics SA

    Get the next $ADCT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ADCT

    DatePrice TargetRatingAnalyst
    11/8/2024$6.00Overweight
    Stephens
    5/30/2024Overweight
    Cantor Fitzgerald
    3/28/2024$11.00Buy
    Guggenheim
    8/10/2023Underweight → Neutral
    JP Morgan
    4/24/2023$7.00 → $2.00Neutral → Underperform
    BofA Securities
    12/6/2022$12.00Overweight
    CapitalOne
    11/9/2022$14.00 → $7.00Buy → Neutral
    BofA Securities
    9/21/2022$5.00Overweight
    JP Morgan
    More analyst ratings

    $ADCT
    SEC Filings

    See more
    • SEC Form S-3 filed by ADC Therapeutics SA

      S-3 - ADC Therapeutics SA (0001771910) (Filer)

      6/30/25 5:28:28 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by ADC Therapeutics SA

      SCHEDULE 13G - ADC Therapeutics SA (0001771910) (Subject)

      6/17/25 5:28:58 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADC Therapeutics SA filed SEC Form 8-K: Entry into a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - ADC Therapeutics SA (0001771910) (Filer)

      6/12/25 9:01:23 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

      Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-5) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

      10/13/22 1:04:01 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

      Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-4) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

      10/13/22 1:03:14 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

      Submission status for ADC Therapeutics SA's drug ZYNLONTA (ORIG-1) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 04/23/2021. Application Category: BLA, Application Number: 761196, Application Classification:

      4/23/21 1:46:03 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stephens initiated coverage on ADC Therapeutics with a new price target

      Stephens initiated coverage of ADC Therapeutics with a rating of Overweight and set a new price target of $6.00

      11/8/24 7:32:36 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on ADC Therapeutics

      Cantor Fitzgerald initiated coverage of ADC Therapeutics with a rating of Overweight

      5/30/24 7:26:04 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on ADC Therapeutics with a new price target

      Guggenheim initiated coverage of ADC Therapeutics with a rating of Buy and set a new price target of $11.00

      3/28/24 7:31:32 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Squarer Ron covered exercise/tax liability with 15,184 shares, decreasing direct ownership by 14% to 93,627 units (SEC Form 4)

      4 - ADC Therapeutics SA (0001771910) (Issuer)

      6/17/25 5:03:44 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sandor Victor covered exercise/tax liability with 12,600 shares, decreasing direct ownership by 10% to 108,286 units (SEC Form 4)

      4 - ADC Therapeutics SA (0001771910) (Issuer)

      6/17/25 5:03:18 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Monges Viviane covered exercise/tax liability with 2,584 shares, decreasing direct ownership by 2% to 144,043 units (SEC Form 4)

      4 - ADC Therapeutics SA (0001771910) (Issuer)

      6/17/25 5:02:50 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Redmile Group, Llc bought $609,000 worth of shares (200,000 units at $3.04) (SEC Form 4)

      4 - ADC Therapeutics SA (0001771910) (Issuer)

      12/13/24 9:00:14 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Redmile Group, Llc bought $2,248,000 worth of shares (800,000 units at $2.81) (SEC Form 4)

      4 - ADC Therapeutics SA (0001771910) (Issuer)

      7/3/24 8:00:13 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Leadership Updates

    Live Leadership Updates

    See more
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

      £90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova PartnersFunds will be used to build out Myricx Bio's proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigensCompany to establish laboratory operations in London's biotech hub, and expand its management and R&D teamsMichael Bauer from Novo Holdings and Lucille Conroy from Abi

      7/8/24 2:00:00 AM ET
      $ADCT
      $CG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Investment Managers
      Finance
    • ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

      LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. "We are pleased to be joining the Russell 2000® Index," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This is a significant benchmark validating the focused execution of our corporate and capital allocation strategy and our progress toward multiple upcoming expected milestones throughout our hematology and solid tumor portfolios." Th

      6/27/24 7:15:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ADC Therapeutics Makes Grant to New Employee Under Inducement Plan

      LAUSANNE, Switzerland, July 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 17,000 of the Company's common shares to one new employee on July 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate a

      7/1/25 4:05:00 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

      Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response (CR) rate of 69% CR maintained in 17 of 18 patients who achieved CR, with longest duration of CR of 27 months from start of treatment ZYNLONTA was generally well tolerated and safety was consistent with known profile LAUSANNE, Switzerland, June 16, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from a Phase 2 multicenter investigator-initiated trial (IIT) of ZYNLONTA® to treat relapsed/refractory marginal zone lymphoma (r/r MZL) will be

      6/16/25 7:15:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Financials

    Live finance-specific insights

    See more
    • ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

      ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% across 30 efficacy evaluable patients 25 of 26 patients achieving CR remained in CR as of the data cut-off Initial data show the combination is generally well tolerated with a manageable safety profile Company expanding enrollment for LOTIS-7 to 100 patients at 150 µg/kg dose Company to host conference call today at 8:00 a.m. ET/2:00 p.m. CEST LAUSANNE, Switzerland, June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of

      6/12/25 6:30:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

      LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML); ZYNLONTA® plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability Forty patient enrollment reached in LOTIS-7 trial dose expansion arm in patients with relapsed/refractory DLBCL Cash runway expected to fund multiple catalysts into the second half of 2026 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 14, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (

      5/14/25 8:00:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

      LAUSANNE, Switzerland, May 8, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 8:30 a.m. EDT to report financial results for the first quarter 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event,

      5/8/25 7:15:00 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

      SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

      11/14/24 9:00:57 PM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

      SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

      11/13/24 8:58:56 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

      SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

      11/13/24 8:30:55 AM ET
      $ADCT
      Biotechnology: Pharmaceutical Preparations
      Health Care